Innova Captab

Panchkula, India Founded: 2006 • Age: 20 yrs Listed
Pharmaceutical formulations are manufactured by Innova Captab as a CDMO.

About Innova Captab

Innova Captab is a publicly listed company based in Panchkula (India) founded in 2006 by Manoj Agarwal and Vinay Agarwal. Pharmaceutical formulations are manufactured by Innova Captab as a CDMO. The company has 782 employees. Innova Captab has completed 1 acquisition, including Sharon Bio. Its chief executive, as recorded, is Ajay Jain. Its Indian entity Innova Captab Limited reported revenue of β‚Ή1,637 Cr. Innova Captab offers products and services including CDMO Services, Domestic Branded Generics, and International Branded Generics. Its focus areas include Biopharma Outsourcing, Diversified and Small Molecules & Peptides.

Company details

Innova Captab is a CMO manufacturing pharmaceutical formulations in a variety of dosage forms. The company has 2 plants, out of which one is dedicated to the commercial manufacture of cephalosporin formulations in dosage forms such as tablets, capsules, dry syrups and dry injections, while the other is capable of manufacturing general tablet, capsule and ointment type formulations. The company claims that their facilities comply with the cGMP requirements of US FDA, UK MHRA, EU regulations, and, Schedule-M requirements of Indian Drugs and Cosmetics Act. Their clientele includes companies such as Abbott, Lupin and Wockhardt.

  • Headquarters Panchkula, India
  • Employees 782
  • Founders Manoj Agarwal, Vinay Agarwal
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website innovacaptab.com
  • Social LinkedIn
  • Legal Name Innova Captab Limited
Key Metrics
  • Market Cap
    ₹5,938 Cr

    INNOVACAP · NSE

  • Share Price
    ₹1,050.10

    +1.19% today

  • Revenue
    ₹1,630 Cr

    FY 2025-26 · +31.1% YoY

  • EBITDA
    ₹243 Cr

    Margin 14.9%

  • Net Profit
    ₹140 Cr

    FY 2025-26 · +9.3% YoY

  • P/E (TTM)
    35.2x

    P/B 5.0x

  • ROE
    13.8%

    ROCE 14.9%

  • Debt / Equity
    0.33

    Interest cover 8.6x

  • Employee Count
    782
  • Investments & Acquisitions

Products & Services of Innova Captab

Innova Captab offers a comprehensive portfolio of products and services, including CDMO Services, Domestic Branded Generics, and International Branded Generics.

CDMO Services
Contract Manufacturing

Provides development and manufacturing for pharmaceutical companies.

Domestic Branded Generics
Generic Drugs

Offers affordable branded generic medicines in India.

International Branded Generics
Export Pharmaceuticals

Supplies branded generics to global markets.

Board of directors of Innova Captab Limited (Innova Captab)

Innova Captab Limited is the primary company behind Innova Captab. The boards of the 3 registered companies of Innova Captab currently have 12 directors; the longest-serving is Manoj Kumar Lohariwala, appointed in 2004. 31 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Manoj Kumar Lohariwala
DIN 00144656
Director09 Dec 200421 yrs 11 moNugenic Pharma Private Limited, Univentis Medicare Limited, Innova Captab Limited
Vinay Kumar Lohariwala
DIN 00144700
Director09 Dec 200421 yrs 11 moNugenic Pharma Private Limited, Univentis Medicare Limited, Innova Captab Limited
Rohit Lohariwala
DIN 06543263
Director20 Mar 201412 yrs 7 moNugenic Pharma Private Limited
Jayant Vasudeo Rao
DIN 03627850
Whole-time director22 Nov 20178 yrs 11 moInnova Captab Limited
Anup Agarwal
DIN 05118963
Director10 Jun 20206 yrs 5 moUniventis Medicare Limited
Rahul Luhariwala
DIN 09345528
Director21 Oct 20215 yrsNugenic Pharma Private Limited
Shirish Gundopant Belapure
DIN 02219458
Director01 Apr 20224 yrs 7 moInnova Captab Limited
Sudhir Kumar Bassi
DIN 07819617
Director01 Apr 20224 yrs 7 moInnova Captab Limited
Priyanka Dixit
DIN 06578720
Director01 Apr 20224 yrs 7 moInnova Captab Limited
Archit Aggarwal
DIN 08127356
Director01 Apr 20224 yrs 7 moInnova Captab Limited
Mahendar Korthiwada
DIN 09558992
Director28 Apr 20224 yrs 6 moUniventis Medicare Limited, Innova Captab Limited
Riteshe Paltani
DIN 05316034
Whole-time director19 May 20251 yr 6 moUniventis Medicare Limited

People of Innova Captab

19 people are tracked at Innova Captab (9 in leadership, 10 in team); the tracked headcount is 782.

NameRoleGroup
Manoj Agarwal
Co-Founder & Managing DirectorLeadership
Vinay Agarwal
Co-FounderLeadership
Ajay Jain
CEOLeadership
Parveen Singh
Assistant General Manager Human ResourcesLeadership
Managing DirectorLeadership
Rishi Gupta
Group Chief Financial OfficerLeadership
Himanshu Agarwal
General Manager International BusinessLeadership
Sujit Kumar Dana
Vice President & Head -r&dLeadership
Jatinder Singh
Head -drug Regulatory AffairsLeadership
Shivam Bansal
Finance ManagerTeam
Jitendra Kumar
Deputy Manager Quality AssuranceTeam
Mohit Sharma
Account ExecutiveTeam
Neha Khurpa
Sr. Executive DRATeam
Abhishek Sambyal
Senior OfficerTeam
Bhupinder Rana
HR ManagerTeam
Shyam Sharma
Jr. IPQA Officer At Innova Captab Ltd.Team
Shikha S.
QA OfficerTeam
Rajiv Kumar
Assistant ManagerTeam
Divya Sharma
Research AssociateTeam
Premium access

Complete people profiles for Innova Captab

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Innova Captab

Innova Captab is a publicly listed company on the NSE with ticker symbol INNOVACAP in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date29 Dec 2023
  • Listed onBSE: 544067 · NSE: INNOVACAP
  • Listed entityInnova Captab Limited
  • Exchange sectorHealth technology
  • ISININE0DUT01020
  • Share price₹1,053.40 (-1.08% on the day) · 2026-10-14
  • Market capitalisation₹6,095 Cr
  • Price to earnings38.6
  • EPS (diluted, trailing year)₹27.31
  • Dividend yield0.19%
  • Volume (last session)39,790

Financials of Innova Captab

Exchange-reported figures of Innova Captab Limited, the listed company behind Innova Captab (NSE: INNOVACAP).

Financial Highlights

FY 2025-26 Β· Consolidated
Revenue
₹1,630 Cr
+31.1% YoY
EBITDA
₹243 Cr
+30.5% YoY
Profit After Tax
₹140 Cr
+9.3% YoY
Net Worth
₹1,091 Cr
+13.7% YoY
Total Assets
₹1,446 Cr
+10.6% YoY
Total Debt
₹344 Cr
+1.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,6301,2441,081926801411373
Revenue growth+31.1%+15.0%+16.7%+15.7%+94.9%+10.0%-
EBITDA24318615411496.0254.4850.93
EBITDA margin+14.9%+15.0%+14.3%+12.3%+12.0%+13.3%+13.6%
Profit before tax18817113091.7985.7246.3337.52
Net profit14012894.3266.2863.9634.3727.87
Net profit margin+8.6%+10.3%+8.7%+7.2%+8.0%+8.4%+7.5%
EPS (β‚Ή)24.6322.4116.4914.16532.94287.50232.38
Balance sheet
Total assets1,4461,3071,085524410192165
Net worth1,091959831323209145110
Total debt34433824519019945.5054.07
Cash & bank3.8768.1786.7518.882.4411.895.18
Net working capital51543634926621694.4592.77
Cash flow
Cash from operations11763.8414667.1258.9041.5730.80
Cash from investing(107)(152)(499)(90.84)(188)(19.67)(6.04)
Cash from financing(21.72)91.5336127.09125(19.34)(23.28)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue496471448450380352315316
Revenue growth (YoY)+30.5%+33.9%+42.3%+42.3%+19.5%+19.5%--
Other income2.462.011.561.654.194.483.384.33
EBITDA69.9473.1265.0969.3951.8652.1047.6846.56
EBITDA margin+14.1%+15.5%+14.5%+15.4%+13.6%+14.8%+15.1%+14.7%
Depreciation11.8411.7111.3911.4211.3211.059.805.13
Interest4.274.434.593.955.502.861.950.17
Profit before tax56.2958.9950.6755.6739.2342.6739.3145.59
Tax13.8714.8612.5913.539.5711.679.7411.39
Net profit42.4244.1338.0842.1429.6631.0029.5734.20
EPS (β‚Ή)7.407.716.657.375.185.425.175.97
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,299958865859785411373
Revenue growth+35.6%+10.8%+0.7%+9.3%+91.3%+10.0%-
EBITDA15112210898.5298.5154.4850.93
EBITDA margin+11.7%+12.8%+12.5%+11.5%+12.5%+13.3%+13.6%
Profit before tax11212093.7078.2988.6446.3337.52
Net profit83.6789.5269.5555.8866.1934.3727.87
Net profit margin+6.4%+9.3%+8.0%+6.5%+8.4%+8.4%+7.5%
EPS (β‚Ή)14.6315.6311.9111.9955.15287.50232.38
Balance sheet
Total assets1,2151,146970516390192165
Net worth887813724315211145110
Total debt32132924419017645.0354.07
Cash & bank1.9967.8986.3514.992.1911.895.18
Net working capital40032325822016094.3492.77
Cash flow
Cash from operations34.1119.8011239.2858.3441.5730.80
Cash from investing(14.06)(99.75)(472)(87.53)(188)(19.67)(6.04)
Cash from financing(33.99)83.8636851.29125(19.33)(23.28)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue405400358364290287243249
Revenue growth (YoY)+39.7%+39.6%+47.7%+46.4%+20.7%+26.5%--
Other income2.902.702.683.214.634.324.363.49
Total expenses352346320317261252214216
EBITDA52.9754.0538.6447.0029.3234.8228.1832.50
EBITDA margin+13.1%+13.5%+10.8%+12.9%+10.1%+12.1%+11.6%+13.1%
Depreciation9.899.689.409.419.489.087.813.08
Interest3.954.033.983.475.212.771.870.13
Profit before tax42.0343.0427.9437.3319.2627.2922.8632.78
Tax10.0510.976.789.434.937.005.738.37

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 18 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue496471448450380352315316
Revenue growth (YoY)+30.5%+33.9%+42.3%+42.3%+19.5%+19.5%--
Other income2.462.011.561.654.194.483.384.33
EBITDA69.9473.1265.0969.3951.8652.1047.6846.56
EBITDA margin+14.1%+15.5%+14.5%+15.4%+13.6%+14.8%+15.1%+14.7%
Depreciation11.8411.7111.3911.4211.3211.059.805.13
Interest4.274.434.593.955.502.861.950.17
Profit before tax56.2958.9950.6755.6739.2342.6739.3145.59
Tax13.8714.8612.5913.539.5711.679.7411.39
Net profit42.4244.1338.0842.1429.6631.0029.5734.20
EPS (β‚Ή)7.407.716.657.375.185.425.175.97
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,6301,2441,081926801411373
Revenue growth+31.1%+15.0%+16.7%+15.7%+94.9%+10.0%-
Other income7.4212.0512.499.202.881.371.30
Total expenses1,3871,058927813705356322
Employee cost16711790.6654.8040.4622.3320.24
EBITDA24318615411496.0254.4850.93
EBITDA margin+14.9%+15.0%+14.3%+12.3%+12.0%+13.3%+13.6%
Depreciation45.1824.7815.9611.087.505.5910.08
Interest16.902.4121.4619.975.683.934.63
Profit before tax18817113091.7985.7246.3337.52
Tax47.3542.7635.1823.8421.7711.859.65
Net profit14012894.3266.2863.9634.3727.87
Net profit margin+8.6%+10.3%+8.7%+7.2%+8.0%+8.4%+7.5%
EPS (β‚Ή)24.6322.4116.4914.16532.94287.50232.38
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital57.2357.2357.2394.8512.0012.0012.00
Reserves & surplus1,03490277422919713398.35
Shareholders' funds (net worth)1,091959831323209145110
Minority interest0.000.000.000.000.000.000.00
Secured loans34233524116314937.9442.76
Unsecured loans1.962.944.0527.2650.057.5611.31
Total debt34433824519019945.5054.07
Total liabilities1,4461,3071,085524410192165
Assets
Gross block95690140621620510794.26
Net block84283035818318379.1473.16
Capital work in progress15.5022.5234121.540.037.260.00
Investments41.290.000.000.000.000.000.00
Inventories28320814411712891.4565.49
Sundry debtors43733228826521313986.77
Cash & bank balances3.8768.1786.7518.882.4411.895.18
Loans & advances15787.8860.5041.0635.5428.5713.63
Total current assets882696580442379270171
Total current liabilities36726023117616317678.30
Net working capital51543634926621694.4592.77
Total assets1,4461,3071,085524410192165
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash15.5211.733.530.154.802.240.75
Net cash from operating activities11763.8414667.1258.9041.5730.80
Net cash from investing activities(107)(152)(499)(90.84)(188)(19.67)(6.04)
Net cash from financing activities(21.72)91.5336127.09125(19.34)(23.28)
Net change in cash(12.32)3.798.203.37(4.64)2.561.48
Closing cash3.8768.1786.7518.882.4411.895.18
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+31.1%+15.0%+16.7%+15.7%+94.9%+10.0%-
EBITDA growth+30.5%+20.5%+35.9%+18.4%+76.3%+7.0%-
PBT growth+10.1%+32.0%+41.1%+7.1%+85.0%+23.5%+51.6%
Net income growth+9.3%+36.1%+42.3%+3.6%+86.1%+23.3%-
Revenue CAGR (3Y)+20.7%+15.8%+38.1%+35.4%+31.0%--
EBITDA CAGR (3Y)+28.8%+24.7%+41.5%+30.7%+33.0%--
Profitability & leverage
Net income margin+8.6%+10.3%+8.7%+7.3%+8.0%+8.4%+7.5%
Return on capital employed+14.9%+14.5%+18.8%+23.9%+30.4%+28.2%+26.3%
Return on net worth+13.8%+14.3%+17.0%+28.0%+36.2%+27.0%+28.9%
Debt / equity0.330.330.380.730.690.390.65
Long-term debt / equity0.220.250.260.290.210.070.20
Interest cover8.551.4915.5019.476.428.0411.33
Efficiency & per share
Fixed asset turnover1.761.903.474.395.134.094.06
Inventory turnover6.647.078.287.547.285.237.16
Debtors turnover4.244.013.913.884.563.654.20
EPS (β‚Ή)24.6322.4116.4914.16532.94287.50232.38
Dividend per share (β‚Ή)2.000.000.000.000.000.000.00
Book value per share (β‚Ή)190.61167.66145.2057.611,738.381,206.84919.62
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue405400358364290287243249
Revenue growth (YoY)+39.7%+39.6%+47.7%+46.4%+20.7%+26.5%--
Other income2.902.702.683.214.634.324.363.49
Total expenses352346320317261252214216
EBITDA52.9754.0538.6447.0029.3234.8228.1832.50
EBITDA margin+13.1%+13.5%+10.8%+12.9%+10.1%+12.1%+11.6%+13.1%
Depreciation9.899.689.409.419.489.087.813.08
Interest3.954.033.983.475.212.771.870.13
Profit before tax42.0343.0427.9437.3319.2627.2922.8632.78
Tax10.0510.976.789.434.937.005.738.37
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,299958865859785411373
Revenue growth+35.6%+10.8%+0.7%+9.3%+91.3%+10.0%-
Other income13.2416.7810.728.732.861.371.30
Total expenses1,147836757760687356322
Employee cost11162.7450.1143.6036.3022.2220.24
EBITDA15112210898.5298.5154.4850.93
EBITDA margin+11.7%+12.8%+12.5%+11.5%+12.5%+13.3%+13.6%
Depreciation37.3717.0211.4010.667.405.5910.08
Interest15.422.1713.5918.305.333.934.63
Profit before tax11212093.7078.2988.6446.3337.52
Tax28.1430.4225.5320.7522.4611.859.65
Net profit83.6789.5269.5555.8866.1934.3727.87
Net profit margin+6.4%+9.3%+8.0%+6.5%+8.4%+8.4%+7.5%
EPS (β‚Ή)14.6315.6311.9111.9955.15287.50232.38
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital57.2357.2357.2394.8512.0012.0012.00
Reserves & surplus82975666622019913398.35
Shareholders' funds (net worth)887813724315211145110
Secured loans31932624016313937.9442.76
Unsecured loans1.952.913.8627.0736.997.0911.31
Total debt32132924419017645.0354.07
Total liabilities1,2151,146970516390192165
Assets
Gross block74569820819518594.9383.23
Net block64863716416116179.1473.15
Capital work in progress15.2721.0233921.540.037.260.00
Investments10160.0060.0060.0060.000.000.00
Inventories20414093.9997.2710591.4565.49
Sundry debtors33024921723017413986.77
Cash & bank balances1.9967.8986.3514.992.1911.895.18
Loans & advances17272.3739.7036.4531.9528.5713.63
Total current assets709529437378313270171
Total current liabilities30920618015815317678.30
Net working capital40032325822016094.3492.77
Total assets1,2151,146970516390192165
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash15.3111.393.140.104.802.230.75
Net cash from operating activities34.1119.8011239.2858.3441.5730.80
Net cash from investing activities(14.06)(99.75)(472)(87.53)(188)(19.67)(6.04)
Net cash from financing activities(33.99)83.8636851.29125(19.33)(23.28)
Net change in cash(13.94)3.928.253.03(4.69)2.561.48
Closing cash1.9967.8986.3514.992.1911.895.18
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+35.6%+10.8%+0.7%+9.3%+91.3%+10.0%-
EBITDA growth+23.8%+13.3%+9.6%+0.0%+80.8%+7.0%-
PBT growth-6.7%+27.9%+19.7%-11.7%+91.3%+23.5%+9997.0%
Net income growth-6.5%+28.7%+24.5%-15.6%+92.6%+23.3%-
Revenue CAGR (3Y)+14.8%+6.9%+28.2%+32.0%---
EBITDA CAGR (3Y)+15.4%+7.5%+25.6%+24.6%---
Profitability & leverage
Net income margin+6.4%+9.3%+7.9%+6.7%+8.4%+8.4%+7.5%
Return on capital employed+10.8%+11.5%+14.4%+21.3%+32.3%+28.2%+25.5%
Return on net worth+9.9%+11.6%+13.7%+24.0%+37.2%+27.0%+25.3%
Debt / equity0.380.370.420.700.620.390.49
Long-term debt / equity0.270.300.290.300.210.070.11
Interest cover13.532.0614.0720.835.858.0411.33
Efficiency & per share
Fixed asset turnover1.802.114.294.525.614.614.49
Inventory turnover7.558.199.048.487.985.235.70
Debtors turnover4.494.113.874.265.033.654.30
EPS (β‚Ή)14.6315.6311.9111.9955.15287.50232.38
Dividend per share (β‚Ή)2.000.000.000.000.000.000.00
Book value per share (β‚Ή)154.94142.06126.4755.90175.691,206.84919.62

Investments & Acquisitions by Innova Captab

Innova Captab has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Sharon Bio.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Manufacturer of pharmaceutical intermediates, actives, and finished dosages
sharonbio.comNavi Mumbai, India1989Jun 2023β€’β€’β€’β€’
Premium access

Complete acquisition details for Innova Captab

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Innova Captab

3 dated milestones of Innova Captab across 17 years, from founding to its latest funding, stage changes and deals.

  1. Founded Innova Captab is founded.
  2. Acquisition Acquires Sharon Bio.
  3. IPO Lists on the stock exchange (IPO).

Web traffic of Innova Captab

The website of Innova Captab (innovacaptab.com) receives about 2.7K visits a month.

  • Monthly visits
    2.7K

    ▼ 22.4% vs previous month

Similar websites

Websites whose visitors overlap most with Innova Captab. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
hindustanfoodslimited.com
100%
11.9K#1,697,428View details
axiscapital.co.in
82%
#717,797View details
tiindia.com
49%
24.6K#1,268,205View details
acmegenerics.in
29%
1.9K#7,893,927View details
swissgarnier.com
29%
1.1K#13,288,880View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 9 similar websites and full traffic analytics for Innova Captab

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 9 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Innova Captab (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Innova Captab

INNOVACAP: Q2 EBITDA 699.4M RUPEES VS 518.6M (YOY); Q2 EBITDA MARGIN 14.09% VS 13.63% (YOY)
Exchange Update β€’ 5 days ago
INNOVACAP: Q2 CONS NET PROFIT 424.2M RUPEES VS 296.7M (YOY)
Exchange Update β€’ 5 days ago
INNOVACAP: Q2 REVENUE 4.96B RUPEES VS 3.8B (YOY)
Exchange Update β€’ 5 days ago
INNOVACAP: RS. 194.40 CRORES BSE BLOCK TRADE; FOR ~ 1,800,000 SHARES, AT RS. 1080.00
Exchange Update β€’ 1 month ago
Premium access

Complete news archive for Innova Captab

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Innova Captab

Innova Captab was founded in 2006.

Innova Captab is headquartered in Panchkula, India. It is registered at Panchkula, Haryana, India.

Ajay Jain is the CEO of Innova Captab, as recorded in our data.

Innova Captab has 782 employees.

The primary company behind Innova Captab, Innova Captab Limited, reported revenue of β‚Ή1,637 Cr for FY 2026, up 31% year on year.

Innova Captab is a CMO manufacturing pharmaceutical formulations in a variety of dosage forms. The company has 2 plants, out of which one is dedicated to the commercial manufacture of cephalosporin formulations in dosage forms such as tablets, capsules, dry syrups and dry injections, while the other is capable of manufacturing general tablet, capsule and ointment type formulations. The company claims that their facilities comply with the cGMP requirements of US FDA, UK MHRA, EU regulations, and, Schedule-M requirements of Indian Drugs and Cosmetics Act. Their clientele includes companies such as Abbott, Lupin and Wockhardt.

Innova Captab offers CDMO Services, Domestic Branded Generics, and International Branded Generics.

Yes, Innova Captab is publicly traded on NSE under the ticker symbol INNOVACAP.

Innova Captab has made 1 acquisition, including Sharon Bio.

Innova Captab is associated with 3 legal entities: Innova Captab Limited, Nugenic Pharma Private Limited, Univentis Medicare Limited.

The legal entities of Innova Captab currently have 15 directors, including Manoj Kumar Lohariwala, Vinay Kumar Lohariwala, Rohit Lohariwala and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available